Size, Share & Industry Analysis, By Modality (Echocardiography, Cardiac CT, Cardiac MRI, Nuclear Cardiology, Intravascular Imaging, Other Cardiac Imaging), By Care Setting (Hospitals, Specialist Cardiac Centers, Diagnostic Imaging Centers, Ambulatory and Office-Based Facilities), By Clinical Indication (Coronary Artery Disease, Heart Failure and Cardiomyopathy, Valvular and Structural Disease, Arrhythmia and Congenital Disease, Other Indications), By System Configuration (Fixed Standalone Systems, Integrated or Hybrid Systems, Portable and Point-of-Care Systems, Software-Only Imaging Solutions), and Regional Forecast, 2026-2034
Explore the report section by section.
The global Cardiac Imaging Market was valued at USD 13.5 billion in 2025, with a USD 14.4 billion 2026 estimate and USD 23.8 billion forecast for 2034, equivalent to a 6.5% CAGR during 2026–2034.
Cardiac imaging encompasses echocardiography, coronary computed tomography, cardiovascular magnetic resonance, nuclear perfusion imaging and catheter-based coronary visualization. The revenue boundary includes cardiac-focused imaging equipment, dedicated probes and catheters, associated cardiac software, and cardiac imaging services when charged as distinct examinations. It excludes therapeutic stents, unrelated general-radiology scanning and the value of treatment administered after diagnosis. Echocardiography is the largest modality because ventricular function, valve disease and hemodynamics require repeatable assessment across inpatient and outpatient care.
The World Health Organization counted 19.8 million cardiovascular deaths in 2022, including heart attacks and strokes, and reported that more than three quarters occurred in low- and middle-income countries. The American Heart Association 2025 statistics review documents persistent coronary disease, heart failure and valve-related burdens. Clinical demand therefore spans acute diagnosis, risk stratification, follow-up after intervention and longitudinal assessment of chronic conditions. However, imaging capacity differs markedly between tertiary hospitals and smaller community facilities, especially where specialist interpretation is scarce.
The 2024 ESC coronary guidance supports greater use of noninvasive imaging in patients selected by clinical likelihood. The 2024 European Society of Cardiology chronic coronary syndrome guidance favors coronary CT angiography for ruling out obstructive disease in suitable patients and functional imaging for ischemia and viability. GE HealthCare introduced Revolution Vibe in March 2025 with one-beat cardiac CT workflows, while Siemens obtained U.S. clearance for additional photon-counting CT scanners in the same month. Capital expenditure remains substantial, so procurement depends on throughput, reimbursement and trained staff rather than technical capability alone.
The 2025 Philips, Heartflow and Circle CVI announcements concentrated on reconstruction, measurement and quantitative plaque analysis. Philips released Transcend Plus in August 2025 with 26 FDA-cleared cardiovascular ultrasound AI applications; Heartflow announced a next-generation coronary plaque algorithm clearance in September 2025; and Circle Cardiovascular Imaging obtained clearance for its on-premise cvi42 Plaque tool in October. These products target reporting consistency and workflow capacity without requiring every institution to replace its scanner. The forecast combines equipment upgrades, procedural demand and recurring image-analysis software revenue, while acknowledging price pressure in publicly funded health systems.
Source: WHO cardiovascular diseases; AHA 2025 statistics; ESC 2024 guidance; Philips Transcend Plus.
The cardiac imaging market covers equipment, dedicated image-analysis tools and procedure revenue attributable to cardiac diagnostic and image-guided assessment, including repeat examinations for disease surveillance.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Modality | Echocardiography; Cardiac CT; Cardiac MRI; Nuclear Cardiology; Intravascular Imaging; Other Cardiac Imaging |
| By Care Setting | Hospitals; Specialist Cardiac Centers; Diagnostic Imaging Centers; Ambulatory and Office-Based Facilities |
| By Clinical Indication | Coronary Artery Disease; Heart Failure and Cardiomyopathy; Valvular and Structural Disease; Arrhythmia and Congenital Disease; Other Indications |
| By System Configuration | Fixed Standalone Systems; Integrated or Hybrid Systems; Portable and Point-of-Care Systems; Software-Only Imaging Solutions |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; China; Japan; India; Brazil; Mexico; Saudi Arabia; United Arab Emirates |
| Key Market Players | GE HealthCare Technologies Inc.; Siemens Healthineers AG; Koninklijke Philips N.V.; Canon Medical Systems Corporation; FUJIFILM Holdings Corporation; Esaote S.p.A.; Abbott Laboratories; Terumo Corporation; Heartflow Inc.; Circle Cardiovascular Imaging Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Samsung Medison Co., Ltd. |
Cardiac CT includes coronary CT angiography and calcium scoring; MRI includes function, viability and tissue characterization; nuclear cardiology includes SPECT and PET myocardial perfusion. Intravascular imaging includes IVUS, OCT and OFDI systems used to evaluate coronary anatomy. Echocardiography includes transthoracic, transesophageal and intracardiac examinations, with dedicated cardiac probes and interpretation software counted only once within the modality revenue allocation.
Care setting assigns each purchase or examination to the provider billing or owning the equipment, rather than the profession interpreting images. Clinical indications are mutually exclusive according to the primary reason for the study, while configuration describes fixed, hybrid, portable or software-only products. The five-region allocation is based on location of use; no scanner, service charge or software license is counted in more than one member of the same axis.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Growth in chronic cardiovascular follow-up examinations | High | +2.70% | High | High | High |
| Guideline-supported coronary CT and functional imaging | High | +2.00% | High | High | High |
| AI-enabled echocardiography and workflow automation | Medium-High | +1.55% | High | High | Medium |
| Expansion of CT plaque and cardiac MR software | Medium | +1.15% | Medium | High | High |
| Portable imaging access in regional hospitals | Low-Medium | +0.70% | Medium | High | High |
| Others (hybrid systems, PET tracers, interventional guidance) | Low | +0.55% | Medium | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| High scanner capital and maintenance costs | High | -1.10% | High | High | Medium |
| Specialist staffing and uneven reimbursement | Medium-High | -0.75% | High | High | High |
| Contrast safety and radiation considerations | Medium | -0.20% | Medium | Medium | Medium |
| Others (procurement delays, interoperability, price competition) | Low | -0.10% | Medium | Medium | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 6.5% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
WHO recorded 19.8 million cardiovascular deaths globally in 2022, with over three quarters in low- and middle-income economies. Heart failure, coronary disease and valvular abnormalities often require serial assessment rather than a single scan, which supports ongoing ultrasound and cardiac MR utilization. The American Heart Association 2025 statistical update also documents the clinical and economic burden of heart and circulatory conditions. Demand increases when hypertension and diabetes programs identify high-risk patients, but referral pathways and imaging capacity determine how much underlying disease translates into paid examinations.
The ESC 2024 chronic coronary syndrome guidelines favor coronary CT angiography for excluding obstructive coronary artery disease in appropriate patients, while stress imaging assesses ischemia and viability. Hospitals investing in high-resolution CT and perfusion imaging can reduce unnecessary invasive angiography in selected clinical pathways. Siemens Healthineers obtained FDA clearance for additional Naeotom photon-counting CT configurations in March 2025, extending the available scanner range. Adoption is tempered by contrast eligibility, heart-rate control, local expertise and reimbursement rules that differ by payer.
Philips introduced Transcend Plus for EPIQ CVx and Affiniti CVx in August 2025 with 26 FDA-cleared cardiovascular ultrasound AI applications, including automated ejection-fraction measurement. Esaote showcased the portable MyLab C30 cardio system at ESC 2025, targeting mobile examinations and rapid assessments. Such tools reduce repetitive contouring and acquisition tasks, helping sonographers handle growing study volumes without assuming that automation replaces clinical review. Procurement still depends on evidence of repeatability, training, information-system integration and the total cost of probes and maintenance.
Heartflow announced FDA clearance of its next-generation plaque analysis platform in September 2025 and described 95% agreement with intravascular ultrasound for its plaque quantification method. Circle Cardiovascular Imaging obtained clearance for cvi42 Plaque in October 2025, offering on-premise analysis of coronary CT studies. Both developments expand the value of existing CT datasets beyond stenosis reporting, creating demand for segmentation software and workstation integration. The revenue opportunity is constrained by clinical validation, reimbursement eligibility and institutional data-governance requirements.
Photon-counting CT, cardiac MRI and hybrid nuclear systems require expensive rooms, service contracts and specialized personnel. The ESC Atlas cardiovascular statistics for 2025 identify pronounced disparities in healthcare delivery and workforce capacity across more than 50 member countries. Contrast-related renal concerns, radiation-dose management and patient motion further affect modality selection. Public tenders can delay replacements despite rising referrals, while smaller hospitals often prioritize conventional ultrasound before advanced scanners. Leasing, shared reading networks and targeted upgrades can reduce initial expenditure without eliminating lifecycle costs.
Sources: WHO cardiovascular fact sheet; AHA 2025 statistics; ESC chronic coronary guidance and 2025 Atlas; Philips; Siemens Healthineers; Heartflow; Circle CVI; Esaote.
Siemens Healthineers received FDA clearance for its Naeotom Alpha.Pro and Alpha.Prime configurations in March 2025, adding dual-source and single-source photon-counting options. By September, University Hospitals Cleveland had installed an Alpha.Pro system and Siemens reported more than 2 million patient scans worldwide across its photon-counting technology. Higher spatial resolution supports assessment of small coronary structures and complex calcification. Purchasing remains concentrated in large institutions because scanner costs and specialist protocol expertise are substantial, but multiple configurations allow procurement to match volume and case complexity.
Terumo received U.S. 510(k) clearance for OPUSWAVE and its DualView catheter in October 2025, combining optical frequency-domain imaging and intravascular ultrasound in a single system. Abbott introduced Ultreon OCT analysis software in India in October 2023 to help characterize calcified and noncalcified coronary plaque and support stent planning. These technologies add high-resolution intravascular information when angiography alone leaves uncertainty about lesion morphology. They are used primarily in catheterization laboratories and carry procedure-specific costs, so adoption depends on interventional volumes and reimbursement.
The FDA approved GE HealthCare Flyrcado, a flurpiridaz F 18 PET myocardial perfusion tracer, in September 2024 for adults with known or suspected coronary artery disease. Its longer physical half-life relative to existing cardiac PET tracers can enable distribution from offsite pharmacies and potentially support exercise-stress imaging. PET offers quantitative blood-flow assessment, whereas SPECT remains established in many hospitals. Tracer supply chains, radiopharmacy availability and licensing obligations determine whether newer PET protocols can be offered outside specialist centers.
Canon Medical announced a November 2025 global commercial launch of its Alphenix 4D CT with Aquilion ONE INSIGHT Edition, combining angiography and wide-detector CT within one interventional suite. Esaote presented MyLab C30 cardio portable ultrasound in August 2025 for cardiovascular workflows. Integrated suites favor complex hospital procedures, while portable echocardiography supports bedside triage and outreach where full CT infrastructure is impractical. Buyers assess installation footprint, staff training, scanner uptime and image transfer to cardiology workstations before selecting either approach.
Cardiac imaging modality revenue is divided into echocardiography, CT, MRI, nuclear cardiology, intravascular imaging and other examinations. Each study and its directly associated products belong to one primary modality, preventing a coronary CT dataset analyzed with software from being counted twice.
Echocardiography represented an estimated ~38% of 2025 revenue. Repeated valve, ventricular and bedside assessments support high procedure frequency, and portable platforms reduce barriers for emergency and outpatient teams. Philips expanded automated ejection-fraction functions in August 2025, while Esaote introduced a cardio-focused mobile system. Echo remains the first imaging step in many heart failure and structural-disease pathways because it avoids ionizing radiation.
Cardiac CT is positioned for above-average growth as ESC recommendations support coronary CT angiography for appropriate patients with suspected chronic coronary disease. Photon-counting scanners from Siemens and dedicated GE cardiac workflows broaden technical capability. Demand is strongest where noninvasive referral pathways, contrast protocols and reimbursed image interpretation are established. CT also provides datasets for coronary plaque quantification and procedural planning.
Cardiac MRI provides ventricular volumes, tissue characterization and viability information, while PET and SPECT assess perfusion. GE Flyrcado gained FDA approval in September 2024 for PET myocardial perfusion imaging. MRI and nuclear systems require longer examination times and specialized staff than routine ultrasound. Their value is concentrated in complex diagnoses, risk stratification and follow-up where simpler tests are insufficient.
Intravascular ultrasound and optical imaging remain procedure-led niches in catheterization laboratories. Terumo OPUSWAVE combines IVUS and OFDI, while Abbott Ultreon supports OCT interpretation. The other-modality category captures smaller cardiac-specific techniques not assigned to the five named groups.
Cardiac imaging spending is assigned to hospitals, specialist cardiac centers, independent imaging centers or ambulatory and office-based facilities according to the organization delivering the examination. Provider groups are exclusive even when their cardiologists also interpret external studies.
Hospitals represented an estimated ~56% of 2025 revenue because they manage acute chest pain, complex congenital cases, catheter-based procedures and cardiac surgery. Advanced CT, MR and hybrid angiography are typically concentrated in tertiary institutions with intensive-care and specialist support. University Hospitals Cleveland installed Siemens photon-counting CT in 2025, illustrating the role of major hospital systems in early adoption.
Dedicated cardiac centers invest in high-volume echo, stress testing and coronary CT workflows, often with direct referral links to interventional cardiologists. They can standardize protocols and reporting around a narrower case mix than general hospitals. Heartflow and Circle CVI plaque-analysis software support this model by extending CT interpretation capabilities, provided facilities maintain quality assurance and appropriate clinical oversight.
Independent imaging centers primarily provide scheduled CT, MR and ultrasound, while ambulatory and office-based sites emphasize portable echo and lower-acuity follow-up. In regions with limited scanner density, referral networks may pool advanced cardiac studies at a regional hub. Smaller practices face lower capital budgets and depend on predictable reimbursement, so portable systems and subscription analysis tools may be more practical than hybrid suites.
The setting split tracks the owner of each billable procedure or installed system rather than a cardiologist who may read studies from multiple sites. Emergency access, transport requirements and insurer networks influence where patients are ultimately imaged.
Primary clinical indication distinguishes coronary artery disease, heart failure and cardiomyopathy, valvular and structural disease, arrhythmia and congenital disease, and other cardiac assessments. Each examination is classified by the main referral question even when a scan reveals multiple abnormalities.
Coronary disease accounts for the largest modeled indication share because symptomatic assessment, CT angiography, ischemia testing and post-revascularization evaluation generate multiple types of imaging. The 2024 ESC guidance prioritizes CCTA for ruling out obstructive disease in selected patients. GE Flyrcado supports PET perfusion assessment, while Heartflow plaque analysis adds quantitative coronary CT interpretation.
Heart failure and cardiomyopathy create repeat echocardiography demand to evaluate ejection fraction, chamber remodeling and treatment response. Cardiac MRI is used when tissue characterization or infiltrative disease assessment changes management. Philips Transcend Plus includes automated ventricular-function tools intended to reduce measurement variability, and Circle cvi42 supports quantitative MR analysis. Cardiac MRI and echocardiography follow-up intervals vary with symptoms, clinical indication and changes to treatment.
Structural interventions require echocardiographic anatomy, CT measurements and sometimes intracardiac imaging before and during treatment. Philips showcased VeriSight Pro intracardiac echocardiography at ESC 2025, supporting real-time visualization in electrophysiology and structural-heart procedures. Congenital and arrhythmia studies form a separate indication pool, with the remaining category covering risk assessment and other cardiac-specific referrals.
The indication allocation is not a count of diagnosed patients. It is a distribution of imaging revenue by the principal clinical reason for the examination, so serial monitoring can generate additional spending within the same disease group.
Equipment and software are separated into fixed standalone scanners, integrated or hybrid installations, portable and point-of-care devices, and software-only solutions. A hospital with a CT scanner and separate image-analysis subscription allocates each paid product to its actual configuration without duplicating the underlying scan.
Fixed standalone platforms retain the largest configuration share because hospitals and imaging centers rely on room-based CT, MRI, SPECT and high-end echocardiography. GE Revolution Vibe and Siemens Naeotom systems illustrate specialized cardiac performance within multi-use scanners. Capital purchases create substantial upfront revenue, while service and replacement cycles support ongoing spending over the installed equipment life.
Hybrid installations combine angiography, CT or other modalities for interventional guidance. Canon launched Alphenix 4D CT with Aquilion ONE INSIGHT Edition in November 2025, targeting diagnosis and procedural verification in one room. Such configurations demand dedicated infrastructure and cross-disciplinary staffing but can reduce patient transfer between imaging and intervention areas. Canon hybrid CT installations therefore concentrate in larger hospital campuses with dedicated interventional facilities.
Portable echo systems support bedside assessment and regional outreach, while software-only products analyze existing CT and MR datasets. Esaote MyLab C30 cardio represents portable acquisition; Circle cvi42 Plaque and Heartflow offer dedicated post-processing. The economics differ: handheld devices need clinical acquisition training, whereas software subscriptions depend on image quality, IT integration and evidence supporting their outputs.
Portable and software-only categories can gain share without displacing every fixed scanner. The classification describes the product sold rather than its clinical indication, preserving exclusive accounting across the configuration dimension.
Regional demand reflects cardiovascular disease burden, scanner density, payer reimbursement, specialist staffing and the availability of dedicated cardiac software. Regional allocations refer to 2025 imaging revenue rather than the population with cardiovascular disease.
North America represented an estimated ~42% of global cardiac imaging revenue in 2025. The United States combines established coronary CT and cardiac MR reimbursement with high use of echocardiography in heart failure and valvular disease. The AHA 2025 statistics review identifies persistent cardiovascular morbidity that supports diagnostic volumes. Large hospital networks are early adopters of photon-counting CT and quantitative plaque tools, while outpatient facilities compete on scheduling and image-report turnaround. In Canada, provincial purchasing and regional specialist networks moderate the pace of premium scanner upgrades. Cross-border differences in payer coverage mean similar clinical indications can produce different revenue per examination.
Siemens Healthineers announced the first U.S. installation of Naeotom Alpha.Pro at University Hospitals Cleveland in September 2025. Heartflow received FDA clearance for next-generation coronary plaque analysis that month, followed by Circle CVI cvi42 Plaque in October. These milestones demonstrate demand for high-resolution acquisition and CT interpretation, while hospitals still require radiologist review and appropriate reimbursement for clinical use.
Source: Siemens Healthineers.
Circle Cardiovascular Imaging, based in Calgary, announced FDA clearance for its cvi42 Plaque solution in October 2025. Its software supports on-premise coronary plaque quantification and vendor-neutral workflows, capabilities relevant to Canadian hospital networks with strict data-governance requirements. Public procurement, cardiologist availability and centralized MRI capacity influence local deployment more than consumer willingness to pay for scans.
Source: Circle CVI.
Europe combines advanced cardiology centers with nationally administered reimbursement and equipment tenders. The ESC 2024 chronic coronary syndrome guidelines support noninvasive anatomical or functional imaging according to clinical likelihood, strengthening referrals for CCTA, stress echo and cardiac MR. The ESC cardiovascular statistics report for 2025 describes more than 3 million cardiovascular deaths annually across its member countries and wide differences in specialist capacity. German and British providers have strong imaging programs, but procurement cycles and staffing can delay replacement of otherwise serviceable scanners. Italian and Spanish cardiology centers also provide launch venues for portable and hybrid systems.
The ESC chronic coronary syndrome recommendations favor CCTA to exclude obstructive disease and functional imaging for ischemia assessment. German hospitals use these pathways alongside established echocardiography and cardiac MRI services, but equipment procurement is affected by hospital investment budgets and specialist training. Siemens Healthineers expanded its photon-counting CT portfolio in March 2025, giving European buyers more system configurations for different case volumes.
Source: ESC.
The 2025 ESC Atlas identifies uneven access to cardiovascular services across Europe, with workforce capacity an important constraint. UK cardiac imaging programs operate through NHS referral pathways, where timely echo, CT and MR access affects diagnosis and treatment planning. Public-sector buyers prioritize throughput and diagnostic reliability, so automated ventricular-function measurement and integrated reporting are relevant even without immediate scanner replacement.
Source: European Heart Journal.
Asia-Pacific combines premium scanner markets in Japan and Australia with large capacity-expansion opportunities in China and India. Cardiovascular risk factors and population ageing raise demand for coronary imaging, while equipment affordability and sonographer training determine local access. Fujifilm introduced new ARIETTA DeepInsight ultrasound models in Japan in December 2025, and Abbott launched its Ultreon coronary OCT analysis platform in India in 2023. Australian policy continues funding Heart Health Checks, which can identify patients needing specialist referral. Revenue growth will depend on the ability of health systems to translate screening and risk assessment into accessible diagnostic imaging services.
Fujifilm Medical launched ARIETTA 850 DeepInsight x and ARIETTA 750 DeepInsight x ultrasound systems in December 2025, emphasizing image quality and workflow efficiency. Japan has a large older population and substantial cardiac diagnostic capacity, supporting repeated echocardiography and advanced imaging. Purchasing decisions favor reliable service support and protocol standardization, particularly when cardiology and radiology teams share imaging infrastructure.
Source: Fujifilm Medical.
Abbott introduced Ultreon OCT software in India in October 2023, supporting coronary plaque assessment and stent planning in catheterization laboratories. The Indian government launched a nationwide noncommunicable-disease screening drive in February 2025 for adults aged 30 and older, including hypertension and diabetes. Increased detection can generate cardiology referrals, but access to advanced CT and MR remains concentrated in better-resourced urban facilities.
Source: Abbott India.
Latin America has a substantial cardiovascular disease burden but less uniform access to high-end cardiac CT, MRI and PET than North America. Brazil operates a large public health system alongside private imaging chains, creating different equipment replacement schedules and reimbursement economics. The Brazilian statistics agency IBGE recorded 400,154 deaths from circulatory diseases in 2022, while the health ministry maintains cardiovascular mortality data through its SIM system. Portable ultrasound is relevant to distributed care, whereas coronary CT and invasive imaging cluster in specialist hospitals. Currency changes and imported equipment costs can constrain procurement despite clinical need.
IBGE reported 400,154 circulatory-disease deaths in Brazil during 2022, representing a major burden on diagnostic and hospital services. The Ministry of Health updated its acute myocardial infarction care pathway in January 2025 and publishes mortality information through the national SIM system. Public hospitals need broad echo availability, while specialized cardiac centers use CT, catheter imaging and nuclear perfusion to assess selected patients.
Source: IBGE.
Mexico combines public cardiology hospitals with private diagnostic networks that can invest in advanced CT and ultrasound. The 2024 ESC guidance is not a Mexican reimbursement rule, but its emphasis on selecting anatomical versus functional imaging illustrates the clinical tradeoffs relevant to local specialists. Scanner utilization, patient travel time and trained staff influence whether coronary CT can expand beyond major metropolitan centers.
Source: WHO.
Middle East and Africa combines high-capital Gulf hospitals with many African facilities that prioritize affordable echocardiography. At a 2025 Riyadh cardiovascular meeting, WHO Eastern Mediterranean leadership cited more than 50 million cardiovascular cases in the region in 2019 and warned of a potential increase to 108 million by 2045 without action. Advanced CT, cardiac MR and PET are concentrated in large referral hospitals, while portable echo can reach emergency and rural services. Equipment maintenance, specialist availability and public budgets limit expansion in lower-income markets. Saudi Arabia and the UAE are prominent regional purchasers of advanced imaging infrastructure.
WHO Eastern Mediterranean leadership addressed cardiovascular disease at TCT Plus Middle East 2025 in Riyadh, describing the region as facing a large and growing burden. Saudi tertiary hospitals use catheter laboratories and noninvasive imaging to manage complex coronary disease, while regional facilities rely heavily on ultrasound. Investment in advanced CT must be paired with radiographer training, specialist interpretation and reliable maintenance contracts.
Source: WHO EMRO.
UAE specialist hospitals can adopt advanced cardiac imaging through concentrated tertiary facilities and private insurance networks. Philips showcased integrated cardiovascular imaging, intracardiac ultrasound and workflow software at ESC 2025, technologies applicable to high-acuity referral centers. Wider access still depends on physician referral practices, scan capacity and consistent reimbursement rather than hardware procurement alone.
Source: Philips.
Competition spans scanner manufacturers, ultrasound specialists, coronary catheter providers and independent cardiac image-analysis software developers. Revenue concentration differs by modality: large equipment companies dominate CT and MR, while specialist software firms compete on workflow and quantification.
GE introduced Revolution Vibe cardiac CT in March 2025 and markets Flyrcado PET myocardial perfusion tracer following its September 2024 FDA approval. Siemens expanded the Naeotom photon-counting CT class in March 2025 and reported broad clinical uptake. Their advantage includes installed systems, training networks, service capacity and integration with hospital information technology.
Philips released Transcend Plus in August 2025 with 26 FDA-cleared cardiovascular ultrasound AI applications. Esaote showcased MyLab C30 cardio at ESC 2025, and Fujifilm introduced ARIETTA DeepInsight models in Japan later that year. Ultrasound competition is shaped by probe performance, portability, automated measurement and the availability of local technical support.
Abbott markets OCT-based Ultreon analysis for coronary plaque and stent optimization. Terumo received U.S. clearance for the OPUSWAVE dual-sensor system and DualView catheter in October 2025, combining OFDI and IVUS. These suppliers compete within catheter laboratories where procedural efficiency and evidence of imaging-guided intervention influence purchase decisions.
Heartflow gained clearance for next-generation plaque analysis in September 2025 and described new payer coverage. Circle received clearance for cvi42 Plaque in October, offering local processing of coronary CT images. Independent software vendors seek recurring contracts by demonstrating reproducible measurements and interoperability with scanners already installed at cardiology centers.
Canon Medical competes in wide-detector CT and hybrid angiography, announcing the Alphenix 4D CT and Aquilion ONE INSIGHT Edition combination in November 2025. Shenzhen Mindray and Samsung Medison supply ultrasound platforms that broaden competitive options in Asia and cost-sensitive health systems. The strongest product differentiators vary across settings: high-end hospitals emphasize spectral or photon-counting resolution, whereas community sites favor practical workflow and maintenance support.
Circle CVI and Heartflow compete on data processing architecture and payer reimbursement arrangements. Circle CVI positions cvi42 Plaque for on-premise processing, while Heartflow provides cloud-based analysis services with payer arrangements. Hospitals comparing these offerings must evaluate integration costs, regulatory authorization, image quality and clinician oversight. Partnerships with health systems and reference installations can shorten adoption cycles, but software claims require clinical validation and post-market performance monitoring.
October 2025: Terumo Interventional Systems received FDA 510(k) clearance for OPUSWAVE and its DualView catheter, combining optical frequency-domain imaging and intravascular ultrasound. The dual-sensor design provides complementary views of coronary anatomy during interventions. The clearance adds a new option for catheter laboratories assessing lesion morphology and selecting stent strategies, subject to procedural training and reimbursement. Source
October 2025: Circle Cardiovascular Imaging announced U.S. FDA clearance of cvi42 Plaque for coronary artery disease evaluation. The on-premise software quantifies coronary plaque using cardiac CT images without sending data to an external reading service. It targets hospitals seeking control over imaging information and faster post-processing, while still requiring clinician interpretation of results. Source
September 2025: Heartflow received FDA clearance for its next-generation Plaque Analysis algorithm and announced wider Cigna coverage beginning in October. The company reported 95% agreement with intravascular ultrasound for its plaque measurements. This development broadens clinical use of coronary CT datasets and creates a potential recurring software revenue stream for diagnostic imaging programs. Source
August 2025: Philips launched Transcend Plus for EPIQ CVx and Affiniti CVx cardiovascular ultrasound platforms, incorporating 26 FDA-cleared AI applications. Automated ejection-fraction assessment and improved two-dimensional and three-dimensional image quality target repeatability in busy echo laboratories. The product update gives existing cardiovascular ultrasound users additional analysis capabilities without necessarily changing their clinical referral pathways. Source
March 2025: Siemens Healthineers obtained U.S. FDA clearance for its expanded Naeotom Alpha photon-counting CT family, including Alpha.Pro and Alpha.Prime. The configurations broaden access to high-resolution CT acquisition, relevant to coronary anatomy and complex calcified lesions. More than one million patients had been scanned with the technology by the March announcement, according to Siemens. Source
March 2025: GE HealthCare unveiled Revolution Vibe with one-beat cardiac CT capability and automated workflow features at the American College of Cardiology meeting. The company described tools for difficult heart rhythms and calcified coronaries, as well as faster patient preparation. At announcement, the system was CE marked and U.S. 510(k) clearance was pending. Source
Cardiac imaging revenue is projected to rise from USD 14.4 billion in 2026 to USD 23.8 billion in 2034, a 6.5% CAGR as equipment renewal, clinical examinations and dedicated software expand.
| Forecast Variable | 2025–2026 Evidence | Effect Through 2034 |
|---|---|---|
| Disease-related referrals | WHO 19.8 million CVD deaths in 2022 | Sustained imaging demand from diagnosis and surveillance |
| Noninvasive coronary pathways | ESC 2024 CCS imaging guidance | Higher utilization of CCTA and functional assessment |
| Automated echocardiography | Philips 26 cleared applications in 2025 | Improved throughput and replacement value |
| Photon-counting CT | Siemens additional FDA clearances in 2025 | Premium scanner upgrades at large hospitals |
| Coronary plaque analytics | Heartflow and Circle clearances in 2025 | Recurring software and reporting services |
| Cost and workforce | ESC 2025 Atlas access disparities | Moderates diffusion outside tertiary centers |
Echocardiography should retain the largest modality revenue pool because repeat ventricular, valve and bedside examinations are broadly used across care settings. Cardiac CT is positioned for faster growth as the 2024 ESC recommendations support appropriate noninvasive anatomical testing and photon-counting hardware expands scanner options. Premium systems will initially remain concentrated in large referral hospitals; smaller facilities can improve access through portable ultrasound and contracted reading services.
The strongest software opportunity lies in converting existing images into reproducible measurements. Heartflow and Circle CVI obtained 2025 regulatory clearances for plaque analysis, while Philips expanded automated ultrasound measurements. Software revenues can recur through subscriptions, maintenance or per-examination fees, but buyers will assess clinical utility, interoperability, security and payer rules. Standalone software does not eliminate the cost of acquiring a clinically adequate CT or MR dataset.
Asia-Pacific and Latin America offer significant incremental examination volume, yet lower average revenue per scan and uneven scanner density can restrain their share of global value. Australian Heart Health Check funding through 2028 and the 2025 Indian NCD screening drive demonstrate public efforts to identify at-risk populations. The conversion of screening into advanced imaging depends on referral systems, specialist staff and equipment availability. Gulf countries can support premium installations, while many African markets require scalable basic echo services first.
Downside risks include capital-budget constraints, delayed tender cycles, limited trained staff, radiation and contrast safety considerations, and competition among imaging vendors. Upside may come from hybrid angiography suites, new PET tracer distribution and greater adoption of CT-derived plaque assessment. GE Flyrcado, Terumo OPUSWAVE and Canon Alphenix show how specialized products can add value within established clinical pathways. Forecast growth remains sensitive to clinical guideline adoption and reimbursement rather than hardware innovation alone.
Coverage assesses cardiac imaging technologies, clinical indications, care settings, regional access, company strategies and the 2026–2034 revenue trajectory.
The global Cardiac Imaging Market was valued at USD 13.5 billion in 2025. The scope includes dedicated cardiac imaging systems, related software, cardiac-specific consumables and imaging services. It excludes therapeutic devices and unrelated radiology revenue, allowing cardiac CT, echocardiography, MRI, nuclear and intravascular imaging to be compared consistently.
Cardiac imaging revenue is expected to grow at a 6.5% compound annual rate from 2026 through 2034, reaching USD 23.8 billion. Increasing coronary disease assessment, repeated echocardiography, advanced CT hardware and plaque-analysis software support expansion, while staffing and equipment costs restrain adoption.
Echocardiography leads with an estimated 38% of 2025 cardiac imaging revenue. It is widely used for ventricular function, valve disorders and bedside assessment without ionizing radiation. Cardiac CT, MRI, nuclear cardiology and intravascular imaging serve different diagnostic and procedural needs rather than replacing routine echo entirely.
Coronary CT angiography can noninvasively exclude obstructive coronary disease in appropriately selected patients. The 2024 ESC chronic coronary syndrome guidance recommends choosing anatomical or functional imaging according to clinical likelihood and patient characteristics. Photon-counting CT and dedicated plaque-analysis tools extend the information available from coronary CT examinations.
North America accounted for an estimated 42% of 2025 revenue, led by the United States. Established imaging reimbursement, large tertiary hospitals and early adoption of cardiac CT and analysis software support the region. Siemens, Heartflow and Circle announced significant U.S. imaging milestones during 2025.
Cardiac MRI measures chamber volumes and function while characterizing myocardial tissue and viability. It can clarify cardiomyopathy, myocarditis and selected ischemic conditions when ultrasound findings are incomplete. The modality requires specialized scanning protocols and interpretation, so use is concentrated in equipped cardiac centers and hospitals.
AI can automate selected measurements and segmentation but does not replace qualified clinical interpretation. Philips reported 26 FDA-cleared cardiovascular ultrasound AI applications in its 2025 Transcend Plus release, while Heartflow and Circle provide coronary plaque analysis. Clinical teams remain responsible for assessing image quality, patient context and treatment implications.
Major equipment suppliers include GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Fujifilm and Esaote. Heartflow and Circle Cardiovascular Imaging specialize in analysis, while Abbott and Terumo provide intravascular imaging technologies. Mindray and Samsung Medison also compete in ultrasound equipment markets.
Both modalities evaluate myocardial perfusion using radioactive tracers, but PET can provide quantitative myocardial blood-flow assessment and often different image-performance characteristics. GE HealthCare Flyrcado received U.S. FDA approval in September 2024 for PET myocardial perfusion imaging. GE Flyrcado availability, PET scanner access and payer reimbursement influence modality choice.
IVUS visualizes vessel walls with ultrasound, while OCT and OFDI provide high-resolution optical detail useful for lesion and stent assessment. Abbott markets Ultreon OCT software and Terumo obtained 2025 FDA clearance for OPUSWAVE combining OFDI and IVUS. Terumo OPUSWAVE and Abbott Ultreon supplement angiography in selected catheterization procedures.
High scanner purchase prices, service costs, specialist shortages and reimbursement gaps constrain access to advanced CT, MRI and PET. WHO reports that most cardiovascular deaths occur in low- and middle-income countries. Portable echocardiography and regional referral networks can extend diagnostic reach, although complex cases still require tertiary facilities.
Photon-counting CT, automated echo measurements, quantitative coronary plaque analysis and hybrid intervention suites could change purchasing patterns through 2034. Siemens, Philips, Heartflow, Circle and Canon announced relevant advances in 2025. Their commercial impact depends on clinical evidence, regulatory status, staff training and payer coverage.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.